Renata Trabach Santos

Ms. Renata Trabach Santos

orcid

Research Focus & Metrics

Academic Career Length

6Years (2021-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 October 2022 in Cytotherapy
Verified
Journal Article
Closed access
CBCássia Lisboa Braga
Cássia Lisboa Braga
LSLuana Rocha da Silva
Luana Rocha da Silva
Renata Trabach SantosRenata Trabach Santos
Renata Trabach Santos
LCLuiza Rachel Pinheiro de Carvalho
Luiza Rachel Pinheiro de Carvalho
SMSamuel Coelho Mandacaru
Samuel Coelho Mandacaru
PSPedro Silva
Pedro Silva

19 April 2021 in Critical Care Medicine
Verified
Journal Article
Closed access
LCLuiza Rachel Pinheiro de Carvalho
Luiza Rachel Pinheiro de Carvalho
SASoraia Carvalho Abreu
Soraia Carvalho Abreu
LCLigia Lins de Castro
Ligia Lins de Castro
LSLuísa Helena Andrade da Silva
Luísa Helena Andrade da Silva
PSPaula Matos Silva
Paula Matos Silva
PRPatricia Rocco
Patricia Rocco
OBJECTIVES: To ascertain whether systemic administration of mitochondria-rich fraction isolated from mesenchymal stromal cells would reduce lung, kidney, and liver injury in experimental sepsis. DESIGN: Animal study. SETTING: Laboratory investigation. SUBJECTS: Sixty C57BL/6 male mice. INTERVENTIONS: Sepsis was induced by cecal ligation and puncture; sham-operated animals were used as control. At 24 hours after surgery, cecal ligation and puncture and Sham animals were further randomized to receive saline or mitochondria-rich fraction isolated from mesenchymal stromal cells (3 × 106) IV. At 48 hours, survival, peritoneal bacterial load, lung, kidney, and liver injury were analyzed. Furthermore, the effects of mitochondria on oxygen consumption rate and reactive oxygen species production of lung epithelial and endothelial cells were evaluated in vitro. MEASUREMENTS AND MAIN RESULTS: In vitro exposure of lung epithelial and endothelial cells from cecal ligation and puncture animals to mitochondria-rich fraction isolated from mesenchymal stromal cells restored oxygen consumption rate and reduced total reactive oxygen species production. Infusion of exogenous mitochondria-rich fraction from mesenchymal stromal cells (mitotherapy) reduced peritoneal bacterial load, improved lung mechanics and histology, and decreased the expression of interleukin-1β, keratinocyte chemoattractant, indoleamine 2,3-dioxygenase-2, and programmed cell death protein 1 in lung tissue, while increasing keratinocyte growth factor expression and survival rate in cecal ligation and puncture-induced sepsis. Mitotherapy also reduced kidney and liver injury, plasma creatinine levels, and messenger RNA expressions of interleukin-18 in kidney, interleukin-6, indoleamine 2,3-dioxygenase-2, and programmed cell death protein 1 in liver, while increasing nuclear factor erythroid 2-related factor-2 and superoxide dismutase-2 in kidney and interleukin-10 in liver. CONCLUSIONS: Mitotherapy decreased lung, liver, and kidney injury and increased survival rate in cecal ligation and puncture-induced sepsis.

29 July 2023 in Life Sciences
Verified
Journal Article
Closed access
CBCássia Lisboa Braga
Cássia Lisboa Braga
Renata Trabach SantosRenata Trabach Santos
Renata Trabach Santos
CSCarla Medeiros da Silva
Carla Medeiros da Silva
NRNazareth de Novaes Rocha
Nazareth de Novaes Rocha
NFNathane Santanna Felix
Nathane Santanna Felix
PSPedro Silva
Pedro Silva

1 May 2024 in Current Vascular Pharmacology
Verified
Journal Article
Closed access
PDF file
Renata Trabach SantosRenata Trabach Santos
Renata Trabach Santos
MOMaria Eduarda de Sá Freire Onofre
Maria Eduarda de Sá Freire Onofre
DCDayene de Assis Fernandes Caldeira
Dayene de Assis Fernandes Caldeira
AKAdriane Bello Klein
Adriane Bello Klein
PRPatricia Rocco
Patricia Rocco
PSPedro Silva
Pedro Silva
Pulmonary arterial hypertension (PAH) is a progressive disease characterized by an imbalance between vasoactive mediators, which causes vascular remodeling, increased pulmonary vascular resistance, and right ventricular overload, ultimately leading to heart failure and death. A metabolic theory has been suggested to explain the pathophysiology of PAH whereby abnormalities in mitochondrial biogenesis can trigger a hyperproliferative and apoptosis-resistant phenotype in cardiopulmonary and malignant cells, leading to mitochondrial dysfunction, which in turn causes the Warburg effect. This can culminate in the mitophagy of pulmonary vessels and cardiomyocytes. The present narrative review focuses on the pathophysiology of PAH, the pharmacological agents currently available for its treatment, and promising and challenging areas of therapeutic investigation.

29 August 2025 in Stem Cell Research & Therapy
Verified
Journal Article
Open access
PDF file
Renata Trabach SantosRenata Trabach Santos
Renata Trabach Santos
CBCássia Lisboa Braga
Cássia Lisboa Braga
MOMaria Eduarda de Sá Freire Onofre
Maria Eduarda de Sá Freire Onofre
CSCarla Medeiros da Silva
Carla Medeiros da Silva
NRNazareth de Novaes Rocha
Nazareth de Novaes Rocha
PSPedro Silva
Pedro Silva
During pulmonary arterial hypertension (PAH), cardiac cells develop a hypertrophic and apoptosis-resistant phenotype. Mesenchymal stromal cell (MSC) therapy has been shown to mitigate pulmonary vascular remodeling in PAH; however, successful application is limited by low potency and the need for a high number of MSCs. MSCs exposed to hypoxia release more extracellular vesicles (EV)s with different content than normoxia. We aimed to evaluate the proteomic profile and therapeutic effects of EVs derived from normoxia- and hypoxia-preconditioned MSCs on cardiac tissue remodeling in experimental PAH. Isolated bone marrow MSCs were subjected to normoxia (N, 21%O2) or hypoxia (H, 1%O2) for 48 h and EVs were collected from the MSCs by ultracentrifugation. Proteomic data of the EVs were reanalyzed using PatternLab for Proteomics 5.0. Thirty-two male Wistar rats were randomly assigned to PAH plus intraperitoneal monocrotaline (60 mg/kg) or control (CTRL) with saline. On day 14, PAH animals received saline (1 mL/kg; PAH-SAL), EV-N (EVs from 1 × 106 MSCs; PAH-EV-N) or EV-H (EVs from 1 × 106 MSCs; PAH-EV-H) by jugular vein. On day 28, right ventricular systolic pressure (RVSP), pulmonary acceleration time/pulmonary ejection time (PAT/PET) ratio, right ventricle (RV) outflow diameter, and right ventricular hypertrophy (RVH) index were evaluated. The heart was harvested for histologic and molecular biology analyses. Among 695 proteins identified, 203 were present only in EV-H and 51 in EV-N. EV-H was enriched in proteins involved in the negative regulation of mitogen-activated protein kinase and apoptosis pathways. On day 28, both EV-N and EV-H therapies decreased RVSP compared with PAH-SAL (32 ± 5 mmHg and 29 ± 4 mmHg versus 39 ± 2 mmHg; p < 0.01). Only EV-H increased PAT/PET, reduced RV outflow diameter, and the RVH index compared with PAH-SAL. The expressions of c-Myc, a marker of myocardial injury, and p-GSK3β-Ser9, a proliferative marker, were higher in the PAH-SAL group than in the CTRL group. EV-N and EV-H decreased c-Myc expression, but only EV-H significantly reduced p-GSK3β-Ser9. EV-N and EV-H reduced RVSP, but only EV-H improved RVH and RV outflow diameter, increased the PAT/PET ratio, and downregulated GSK3β protein levels. EVs from hypoxia-preconditioned MSCs demonstrated greater cardioprotective effects than those from normoxia-conditioned MSCs.

Verified
Journal Article
Open access
PDF file
MOMaria E. de S. F. Onofre
Maria E. de S. F. Onofre
Renata Trabach SantosRenata Trabach Santos
Renata Trabach Santos
NRNazareth de N. Rocha
Nazareth de N. Rocha
DCDayene De Assis Fernandes Caldeira
Dayene De Assis Fernandes Caldeira
Johnatas Dutra SilvaJohnatas Dutra Silva
Johnatas Dutra Silva
PSPedro Silva
Pedro Silva
Pulmonary arterial hypertension (PAH) is characterized by progressive vascular remodeling and right ventricular (RV) dysfunction, processes that are increasingly associated with disturbances in cellular metabolism. We investigated whether transplantation of exogenous mitochondria derived from bone marrow mesenchymal stromal cells, alone or combined with sildenafil, could improve mitochondrial homeostasis and attenuate cardiopulmonary remodeling in monocrotaline-induced PAH. Male Wistar rats were assigned to control (CTRL, n = 8) or PAH (n = 32) groups. Fourteen days after induction of PAH, animals were randomized to receive saline, sildenafil (20 mg/kg/day for 14 days), intravenous mitochondrial transplantation (100 μg, days 14 and 21), or combined therapy. On day 28, echocardiography, invasive measurement of RV systolic pressure (RVSP), pulmonary vascular histology, gene expression analyses (vimentin, VE-cadherin, and mitochondrial metabolism–related genes), and high-resolution respirometry were performed. All treatments significantly reduced RVSP compared with untreated PAH. Mitochondrial therapy, alone or combined with sildenafil, decreased arteriolar α-smooth muscle actin content, whereas endothelial–mesenchymal transition was attenuated only with combined treatment. Mitochondrial transplantation and sildenafil increased Complex I–dependent respiration, whereas Complex IV activity improved exclusively with mitochondrial therapy. Combined treatment reduced plasma IL-6 and IL-1β levels compared with PAH. Thus, mitochondrial transplantation, particularly when combined with sildenafil, improved RV function, limited pulmonary vascular remodeling, reduced plasma inflammatory markers, and changed key mitochondrial pathways in experimental PAH.